Tuesday, December 10, 2024, 7:15 PM – 8:45 PM CT (8:15 PM – 9:45 PM ET) | San Antonio, Texas
Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer
Part 1 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®
Event Details
7:15 PM – 8:45 PM — Educational Dinner Meeting
Registration and buffet will open at 7:00 PM CT.
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Aditya Bardia, MD, MPH
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive
Cancer Center
Los Angeles, California
Professor Giuseppe Curigliano, MD, PhD
Clinical Director
Division of Early Drug Development
for Innovative Therapy
Co-Chair, Cancer Experimental
Therapeutics Program
Department of Oncology and Hemato-Oncology
University of Milano
European Institute of Oncology
Milano, Italy
Hope S Rugo, MD
Professor of Medicine
Winterhof Family Professor of Breast Cancer
Director, Breast Oncology and
Clinical Trials Education
Medical Director, Cancer Infusion Services
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Antonio C Wolff, MD, FACP, FASCO
Professor of Oncology
Johns Hopkins University
Baltimore, Maryland
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Agenda
7:15 PM – 8:45 PM — Educational Dinner Meeting
Registration and buffet will open at 7:00 PM CT.
MODULE 1: Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff
- Historical guidelines for routine HER2 assessment in patients with newly diagnosed and recurrent breast cancer
- Thresholds for HER2-null, HER2-ultralow and HER2-low status according to IHC and ISH; appropriate testing strategies to identify patients with low levels of HER2 expression
- Accuracy of testing for HER2 in centralized versus regional laboratories; implications for identifying HER2-low and HER2-ultralow disease in community practice
- Ongoing assessments of next-generation sequencing and liquid biopsy to improve accuracy of HER2 testing
- Other novel complementary methodologies for HER2 assessment under investigation for breast cancer; sensitivity of these strategies compared to conventional IHC or ISH in predicting response to anti-HER2 therapy
MODULE 2: Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia
- Historical management approaches for hormone receptor (HR)-positive and HR-negative, HER2-low and HER2-ultralow metastatic breast cancer (mBC); antitumor efficacy observed with established anti-HER2 agents
- Rationale for the clinical activity observed with trastuzumab deruxtecan (T-DXd) in patients with HER2-low and HER2-ultralow breast cancer
- Long-term follow-up data from the Phase III DESTINY-Breast04 study evaluating T-DXd versus chemotherapy for previously treated, HER2-low advanced breast cancer
- Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast06 trial assessing T-DXd versus chemotherapy for HR-positive, HER2-low and HER2-ultralow mBC after one or more lines of endocrine therapy
- Recently presented efficacy and safety data from DESTINY-Breast06
MODULE 3: Practical Application of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow mBC — Prof Curigliano
- Appropriate sequencing of T-DXd vis-à-vis other available therapies for HR-positive and HR-negative, HER2-low mBC
- Considerations with the use of T-DXd for special populations with HER2-low disease (eg, older patients, those with CNS involvement)
- Current role outside of a research setting, if any, of T-DXd for HER2-ultralow mBC
- Spectrum and incidence of common (eg, gastrointestinal [GI] toxicities, myelosuppression) and more serious (eg, interstitial lung disease [ILD], cardiac toxicities) treatment-emergent adverse events observed with T-DXd
- Strategies to monitor for and manage T-DXd-associated ILD and cardiac complications
- Recommended algorithms for mitigating and managing cytopenias, GI side effects and other complications from T-DXd
MODULE 4: Future Directions for HER2-Targeted Therapy for HER2-Low Breast Cancer — Dr Rugo
- Rationale for combining T-DXd with other systemic therapies for HER2-low breast cancer
- Early research findings and ongoing efforts attempting to define the future role of various combination approaches for HER2-low mBC
- Available clinical research findings with and ongoing evaluation of T-DXd for localized HER2-low breast cancer
- Mechanisms of action and structural components of other novel antibody-drug conjugates (ADCs) under development for HER2-low breast cancer; similarities with and differences from T-DXd
- Available efficacy and safety data with and ongoing evaluation of investigational HER2-targeted ADCs for HER2-low breast cancer
- Mechanisms of action of, early data with and ongoing assessment of the HER2-targeted bispecific antibodies zanidatamab and zenocutuzumab for HER2-low breast cancer
CE Information
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Appreciate the incidence and pathological and molecular characteristics of HER2-low and HER2-ultralow breast cancer, and understand the implications of diagnosis of these phenotypes for routine disease management.
- Assess the biological rationale for the use of HER2-directed therapy for patients with HER2-low and HER2-ultralow breast cancer, and determine its current clinical utility in this disease subset.
- Appraise available clinical research establishing the safety and efficacy of HER2-directed antibody-drug conjugate (ADC) therapy for patients with hormone receptor (HR)-positive and HR-negative, HER2-low metastatic breast cancer, and optimally incorporate this strategy into treatment algorithms.
- Recognize Phase III efficacy results establishing the benefit of HER2-directed ADC therapy for patients with HR-positive, HER2-ultralow metastatic breast cancer, and consider the potential role of this novel approach.
- Understand the spectrum, frequency and severity of treatment-emergent adverse events associated with HER2-directed ADCs, and develop strategies to monitor for, prevent and manage these complications.
- Recall the design of ongoing clinical trials evaluating novel strategies for HER2-low and HER2-ultralow breast cancer, and counsel appropriate patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Wolff has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Dr Bardia — Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi. Professor Curigliano — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Menarini Group, Merck, Novartis, Seagen Inc; Contracted Research: Merck; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Scientific Board: Ellipses Pharma; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Pfizer Inc. Dr Rugo — Consulting Agreements: Chugai Pharmaceutical Co Ltd, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Sanofi, Viatris; Contracted Research: Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2024 San Antonio Breast Cancer Symposium is taking place.
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
NOTICE: Registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.